Literature DB >> 26027638

Drug discovery in prostate cancer mouse models.

Kenneth C Valkenburg1, Kenneth J Pienta.   

Abstract

INTRODUCTION: The mouse is an important, though imperfect, organism with which to model human disease and to discover and test novel drugs in a preclinical setting. Many experimental strategies have been used to discover new biological and molecular targets in the mouse, with the hopes of translating these discoveries into novel drugs to treat prostate cancer in humans. Modeling prostate cancer in the mouse, however, has been challenging, and often drugs that work in mice have failed in human trials. AREAS COVERED: The authors discuss the similarities and differences between mice and men; the types of mouse models that exist to model prostate cancer; practical questions one must ask when using a mouse as a model; and potential reasons that drugs do not often translate to humans. They also discuss the current value in using mouse models for drug discovery to treat prostate cancer and what needs are still unmet in field. EXPERT OPINION: With proper planning and following practical guidelines by the researcher, the mouse is a powerful experimental tool. The field lacks genetically engineered metastatic models, and xenograft models do not allow for the study of the immune system during the metastatic process. There remain several important limitations to discovering and testing novel drugs in mice for eventual human use, but these can often be overcome. Overall, mouse modeling is an essential part of prostate cancer research and drug discovery. Emerging technologies and better and ever-increasing forms of communication are moving the field in a hopeful direction.

Entities:  

Keywords:  drug discovery; model organism; mouse models; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26027638      PMCID: PMC5889079          DOI: 10.1517/17460441.2015.1052790

Source DB:  PubMed          Journal:  Expert Opin Drug Discov        ISSN: 1746-0441            Impact factor:   6.098


  163 in total

1.  The LNCaP cell line--a new model for studies on human prostatic carcinoma.

Authors:  J S Horoszewicz; S S Leong; T M Chu; Z L Wajsman; M Friedman; L Papsidero; U Kim; L S Chai; S Kakati; S K Arya; A A Sandberg
Journal:  Prog Clin Biol Res       Date:  1980

2.  SCRIB expression is deregulated in human prostate cancer, and its deficiency in mice promotes prostate neoplasia.

Authors:  Helen B Pearson; Pedro A Perez-Mancera; Lukas E Dow; Andrew Ryan; Pierre Tennstedt; Debora Bogani; Imogen Elsum; Andy Greenfield; David A Tuveson; Ronald Simon; Patrick O Humbert
Journal:  J Clin Invest       Date:  2011-10-03       Impact factor: 14.808

3.  Establishment and serial passage of cell cultures derived from LuCaP xenografts.

Authors:  Sarah R Young; Matthias Saar; Jennifer Santos; Holly M Nguyen; Robert L Vessella; Donna M Peehl
Journal:  Prostate       Date:  2013-06-06       Impact factor: 4.104

4.  Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium.

Authors:  M Stanbrough; I Leav; P W Kwan; G J Bubley; S P Balk
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

Review 5.  Current advances in humanized mouse models.

Authors:  Ryoji Ito; Takeshi Takahashi; Ikumi Katano; Mamoru Ito
Journal:  Cell Mol Immunol       Date:  2012-02-13       Impact factor: 11.530

6.  Hepsin promotes prostate cancer progression and metastasis.

Authors:  Olga Klezovitch; John Chevillet; Janni Mirosevich; Richard L Roberts; Robert J Matusik; Valeri Vasioukhin
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

7.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

8.  A novel method of generating prostate cancer metastases from orthotopic implants.

Authors:  Eva Corey; Janna E Quinn; Robert L Vessella
Journal:  Prostate       Date:  2003-07-01       Impact factor: 4.104

9.  PTEN knockout prostate cancer as a model for experimental immunotherapy.

Authors:  Kazunori Haga; Atsushi Tomioka; Chun-Peng Liao; Takahiro Kimura; Hiroshi Matsumoto; Izumi Ohno; Kip Hermann; Christopher R Logg; Jing Jiao; Motoyoshi Tanaka; Yoshihiko Hirao; Hong Wu; Carol A Kruse; Pradip Roy-Burman; Noriyuki Kasahara
Journal:  J Urol       Date:  2008-11-17       Impact factor: 7.450

10.  T cells induce pre-metastatic osteolytic disease and help bone metastases establishment in a mouse model of metastatic breast cancer.

Authors:  Ana Carolina Monteiro; Ana Carolina Leal; Triciana Gonçalves-Silva; Ana Carolina T Mercadante; Fabiola Kestelman; Sacha Braun Chaves; Ricardo Bentes Azevedo; João P Monteiro; Adriana Bonomo
Journal:  PLoS One       Date:  2013-07-18       Impact factor: 3.240

View more
  5 in total

Review 1.  Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

Authors:  Emma E van der Toom; Haley D Axelrod; Jean J de la Rosette; Theo M de Reijke; Kenneth J Pienta; Kenneth C Valkenburg
Journal:  Nat Rev Urol       Date:  2019-01       Impact factor: 14.432

2.  Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Authors:  Mark A Castanares; Ben T Copeland; Wasim H Chowdhury; Minzhi M Liu; Ronald Rodriguez; Martin G Pomper; Shawn E Lupold; Catherine A Foss
Journal:  Prostate       Date:  2015-10-26       Impact factor: 4.104

3.  Murine Prostate Micro-dissection and Surgical Castration.

Authors:  Kenneth C Valkenburg; Sarah R Amend; Kenneth J Pienta
Journal:  J Vis Exp       Date:  2016-05-11       Impact factor: 1.355

4.  A simple selection-free method for detecting disseminated tumor cells (DTCs) in murine bone marrow.

Authors:  Kenneth C Valkenburg; Sarah R Amend; James E Verdone; Emma E van der Toom; James R Hernandez; Michael A Gorin; Kenneth J Pienta
Journal:  Oncotarget       Date:  2016-10-25

5.  Deletion of tumor suppressors adenomatous polyposis coli and Smad4 in murine luminal epithelial cells causes invasive prostate cancer and loss of androgen receptor expression.

Authors:  Kenneth C Valkenburg; Angelo M De Marzo; Bart O Williams
Journal:  Oncotarget       Date:  2017-05-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.